DaVita (DVA) fundamentals: P/E, valuation, undervalued?
DaVita · Health Care · ref. ETF XLV · price $182.08
In short — DaVita trades at 15.4× earnings (P/E), 10.6× forward, with a net margin of 6.0 % and revenue growth of +5 %. Read: Cheap for the growth (P/E 11 for ~56% growth (PEG 0.2)).
Is DaVita stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$182.08+43.8% over range
Oct 14, 25low $103.87 · high $240.96Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
60% recommend buying · 5 analysts
Valuation : Cheap for the growth — P/E 11 for ~56% growth (PEG 0.2)
Valuation
15.4
P/E (price/earnings)
10.6
Forward P/E
0.28
PEG
—
Price/book (P/B)
$11.7B
Market cap
11.84
EPS
Profitability & growth
6.0 %
Net margin
+5 %
Revenue growth
+56 %
Earnings growth
$13.4B
Total debt
DaVita income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $11.6B | $560M | 4.8 % |
| 2023 | $12.1B | $692M | 5.7 % |
| 2024 | $12.8B | $936M | 7.3 % |
| 2025 | $13.6B | $747M | 5.5 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is DaVita's P/E and is the stock undervalued? What's a good P/E?
DaVita's P/E is 15.4 (forward 10.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is DaVita profitable?
DaVita has a net margin of 6.0 % (EPS 11.84). The company is profitable.
Is DVA stock expensive?
Our read: "Cheap for the growth" — P/E 11 for ~56% growth (PEG 0.2). Cross-check with growth and sector.
💬 A question about DaVita? The JPI assistant answers using our backtest data.
Keep exploring DaVita